* 74 pct improvement in progression-free survival - analyst
* Analyst cites abstract from European cancer meeting
LONDON, Sept 21 Bayer BAYG.DE and Onyx
Pharmaceuticals's ONXX.O cancer pill Nexavar has demonstrated
impressive results in treating breast tumours, brokerage Baird
said on Monday, citing an abstract from a medical congress.
Nexavar, when combined with standard chemotherapy agent
Xeloda, helped keep tumours in check for longer than in a
control group of patients receiving Xeloda only in the Phase II
Patients given Nexavar plus Xeloda had a 74 percent
improvement in the time they lived without their disease
The new drug combination delayed progression by 6.4 months
compared to 4.1 months for Xeloda alone -- a result which
analyst Christopher Raymond said in a note was "quite striking".
"These data compare quite favorably to other trials in this
setting," he said. "While filing on this trial alone may still
be a long shot, we do now see opportunity for near-term
Xeloda is sold by Switzerland's Roche ROG.VX.
Bayer and Onyx had first announced in July that Nexavar was
promising in breast cancer, but detailed clinical results are
only being presented on Wednesday at the ECCO-ESMO cancer
congress in Berlin.
Nexavar is one of Bayer's most promising drugs, along with
anti-blood clotting pill Xarelto. It is sold as a liver and
kidney cancer treatment in more than 70 countries and Bayer is
also pursuing approvals for use against lung tumours.
The German drugmaker aims to generate worldwide sales of
more than 2 billion euros ($2.9 billion) a year from the drug.
Bayer and U.S. biotech company Onyx are also testing Nexavar
in further ongoing breast cancer studies.
(Editing by Rupert Winchester)